TRYPTAMINE FPO [TYP] (TYP.AX)
TRYPTAMINE FPO [TYP]
301 - 1665 Ellis Street
Kelowna, BC V1Y 2B3
Canada
833-811-8797
https://www.tryptherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. James P. Gilligan MSIB, Ph.D. | President & Chief Scientific Officer | 428.12k | N/D | 1952 |
| Mr. Jim O'Neill | Chief Financial Officer | 133.09k | N/D | N/D |
| Mr. Peter Molloy ASIP, B.A., C.F.A. | Chief Business Officer & Executive Director | 201.5k | N/D | 1972 |
| Mr. Jason Carroll | MD, CEO & Executive Director | N/D | N/D | N/D |
| Dr. William James Garner M.D., M.P.H., MPH | Founder & MD | 61.94k | N/D | 1966 |
| Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. | Chief Medical Officer | N/D | N/D | 1948 |
| Mr. David James Franks BEc, C.A., F Fin, J.P. | Company Secretary | N/D | N/D | 1970 |
Descripción
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de TRYPTAMINE FPO [TYP] a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
